Viewing Opinion | StockChase

Celgene Corp (CELG-Q) opinion on 2017-04-19

Last Price Recorded: 109.0400 on 2017-12-12

ON STOCKCHASE SINCE Jan 2012

Consumer Products
Consumer Products
TOP PICK

Bruce Murray
Celgene Corp was $122.920 at time of opinion
Owned : Yes

One of the surest growth stocks out there. They have a product called Revlimid which treats a whole series of blood cancers. The one they have right now is multiple myeloma, and it prolongs people’s lives substantially. They are going to grow revenue 25% over the next 4 years. It is selling at 18X. Thinks it gets close to $200 in the next couple of years. (Analysts’ price target is $143.)

UNKNOWN

All opinions for CELG-Q (53)

4 BUY
2 BUY on WEAKNESS
8 COMMENT
4 DON'T BUY
3 HOLD
1 PARTIAL BUY
12 PAST TOP PICK
1 SELL
16 TOP PICK
1 WAIT
1 WATCH
View All

More experts covering CELG-Q

SAVE
Add CELG-Q to Watch List

All opinions for CELG-Q (53)

4 BUY
2 BUY on WEAKNESS
8 COMMENT
4 DON'T BUY
3 HOLD
1 PARTIAL BUY
12 PAST TOP PICK
1 SELL
16 TOP PICK
1 WAIT
1 WATCH
View All

More experts covering CELG-Q

SAVE
Add CELG-Q to Watch List

Last 60 Days Opinions

PAST TOP PICK
6 days ago
WAIT
3 weeks ago
PAST TOP PICK
1 month ago
PAST TOP PICK
1 month ago
BUY
1 month ago

No Comments.


You must be logged in to comment.

Successfully Saved Company